Nutra Pharma Corp. Announces Receptopharm, Inc.'s Joint Venture with Chinese Biotechnology Company Zhong Xin Dong Tai Co., Ltd. (Nanogene Biotechnology)

BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has today announced that its drug discovery division, ReceptoPharm, has signed a nonbinding letter of intent with Zhong Xin Dong Tai Co., Ltd. (Nanogene Biotechnology), to create a joint venture in China aimed at developing the Company’s antiviral drug, RPI-MN, for the Chinese market. RPI-MN is ReceptoPharm’s lead drug candidate being researched for the treatment of HIV/AIDS and other viral disorders.